Biotechnology

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

Biotechnology, Pharmaceutical, Health, Initial public offering, Corporate finance, Financial economics, Finance, Money, Karuna, Public offering, Underwriting, Stock market
Tuesday, March 2, 2021 - 2:24am

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (Karuna), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX) (Karuna), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock at a public offering price of $120.00 per share.
  • The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million.
  • In addition, Karuna has granted the underwriters a 30-day option to purchase up to an additional 312,500 shares of common stock.
  • All the shares in the proposed offering are to be sold by Karuna.

Morphic Therapeutic Announces Proposed Public Offering

Life sciences, Biotechnology, Health sciences, Initial public offering, Bookrunner, Corporate finance, Biopharmaceutical, Morphic, Chronic condition
Monday, March 1, 2021 - 9:01pm

In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.

Key Points: 
  • In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Jefferies, Cowen, BMO Capital Markets and RBC Capital Markets are acting as joint bookrunners for the offering.
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Atara, Thousand Oaks, California, Lluís Companys, Spanish politicians, Government of Spain
Monday, March 1, 2021 - 9:05pm

Atara had a very strong year in 2020, delivering on key milestones across the Companys three strategic priorities, said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • Atara had a very strong year in 2020, delivering on key milestones across the Companys three strategic priorities, said Pascal Touchon, President and Chief Executive Officer of Atara.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
  • An archived replay will be available on the Company's website for 30 days following the live webcast.

Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results

Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Asset, Cash, Cash and cash equivalents
Monday, March 1, 2021 - 9:02pm

At December 31, 2020, the company had cash, cash equivalents and short-term investments available for operations of $135.0 million.

Key Points: 
  • At December 31, 2020, the company had cash, cash equivalents and short-term investments available for operations of $135.0 million.
  • Total costs and expenses for the fourth quarter of 2020 were $44.4 million, compared to $51.5 million in the preceding quarter.
  • As of December 31, 2020, Omeros had $135.0 million of cash, cash equivalents and short-term investments available for operations.
  • Omeros management will host a conference call to discuss the financial results and to provide an update on business activities.

Bristol Myers Squibb Announces Dividend

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Bristol Myers Squibb, Companies, Squib, Life sciences, Dividend, Industry economics), Bristol-Myers Squibb, Monoclonal antibodies
Monday, March 1, 2021 - 9:16pm

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.
  • The dividend is payable on May 3, 2021 to stockholders of record at the close of business on April 1, 2021.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Asset, Cash, Cash and cash equivalents
Monday, March 1, 2021 - 9:01pm

On a quarterly basis, total revenue for the three months ended December 31, 2020 was $2.2 million and was relatively flat when compared to the $2.3 million of the quarter ended September 30, 2020.

Key Points: 
  • On a quarterly basis, total revenue for the three months ended December 31, 2020 was $2.2 million and was relatively flat when compared to the $2.3 million of the quarter ended September 30, 2020.
  • On a yearly basis, reported revenues of $9.5 million during the year ended December 31, 2020, decreased from $20.8 million in the year ended December 31, 2019.
  • Operating expenses: On a quarterly basis, total operating expenses for the three months ended December 31, 2020 were $33.3 million compared with $23.3 million for quarter ended September 30, 2020, and $13.8 million in same period of 2019.
  • Cash and Cash Equivalents: The Companys cash balance was $463.0 million as of December 31, 2020, compared to cash and cash equivalents of $301.1 million on September 30, 2020.

Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Biotechnology, Pharmaceutical, Health, SVB Leerink, Underwriting, Companies
Monday, March 1, 2021 - 9:04pm

The estimated net proceeds of the offering to Adamas, after deducting underwriting discounts and commissions and other offering expenses, are expected to be $59.2 million.

Key Points: 
  • The estimated net proceeds of the offering to Adamas, after deducting underwriting discounts and commissions and other offering expenses, are expected to be $59.2 million.
  • SVB Leerink and William Blair acted as joint bookrunning managers for the offering.
  • At Adamas our vision is clear to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society.
  • We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US

Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Cancer treatments, Drugs, Breakthrough therapy, Lung cancer, Orphan drugs, Antineoplastic drugs, Cancer immunotherapy, Pembrolizumab, Small-cell carcinoma, Merkel-cell carcinoma, Non-small-cell lung carcinoma
Monday, March 1, 2021 - 9:05pm

KEYTRUDA remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.

Key Points: 
  • KEYTRUDA remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.
  • We will continue to rigorously evaluate the benefits of KEYTRUDA in small cell lung cancer and other types of cancer, in pursuit of Mercks mission to save and improve lives.
  • KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Biotechnology, Pharmaceutical, Health, Branches of biology, Life sciences, Biology, Stem cells, Geron Corporation, Imetelstat, Telomerase, Geron, Myelodysplastic syndrome, Primary myelofibrosis
Monday, March 1, 2021 - 9:45pm

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Companys website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Companys website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.